Novel marine phenazines as potential cancer chemopreventive and anti-inflammatory agents

Marine Drugs

Volumn 10, Issue 2, 2012, Pages 451-464

  Kondratyuk, Tamara P ^a   Park, Eun Jung ^a   Yu, Rui ^b   Van Breemen, Richard B ^b   Asolkar, Ratnakar N ^c   Murphy, Brian T ^b,c   Fenical, William ^c   Pezzuto, John M ^a  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Apoptosis; Chemoprevention; Inflammation; Lavanducyanin; NF B; Phenazines

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAVANDUCYANIN; LIPOPOLYSACCHARIDE; NATURAL PRODUCT; NITRIC OXIDE; PHENAZINE DERIVATIVE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL STRAIN; BIOSYNTHESIS; CELL COMPARTMENTALIZATION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG IDENTIFICATION; DRUG STRUCTURE; EMBRYO; ENZYME INHIBITION; FERMENTATION MEDIUM; HUMAN; HUMAN CELL; IC 50; MAMMAL CELL; MARINE BACTERIUM; NONHUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; STREPTOMYCES;

MAMMALIA; STREPTOMYCES SP.;

EID: 84858186407     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md10020451     Document Type: Article

References (60)

1. Tergaonkar, V. NFκB pathway: A good signaling paradigm and therapeutic target. Intern. J. Biochem. Cell Biol. 2006, 38, 1647-1653.
2. Aggarwal, B.B.; Sethi, G.; Nair, A.; Ichikawa, H. Nuclear Factor-κB a holy grail in cancer prevention and therapy. Curr. Sign. Transd. Ther. 2006, 1, 25-52.
3. Melisi, D.; Chiao, P.J. NF-κB as a target for cancer therapy. Expert Opin. Ther. Targets 2007, 11, 133-144.
4. Kim, H.J.; Hawke, N.; Baldwin, A.S. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006, 13, 738-747.
5. Pikarsky, E.; Ben-Neriah, Y. NF-κB inhibition: A double-edged sword in cancer? Eur. J. Cancer 2006, 42, 779-784.
6. Luqman, S.; Pezzuto, J.M. NFκB: A promising target for natural products in cancer chemoprevention. Phytother. Res. 2010, 24, 949-963.
7. Yamamoto, Y.; Gaynor, R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest. 2001, 107, 135-142. (Pubitemid 32096826)
8. Gonda, T.A.; Tu, S.; Wang, T.C. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 2009, 8, 2005-2013.
9. Murakami, A. Chemoprevention with phytochemicals targeting inducible nitric oxide synthase. Forum Nutr. 2009, 61, 193-203.
10. Aktan, F. iNOS-mediated nitric oxide production and its regulation. Life Sci. 2004, 75, 639-653. (Pubitemid 38686696)
11. Inoue, J.; Gohda, J.; Akiyama, T.; Semba, K. NF-κB activation in development and progression of cancer. Cancer Sci. 2007, 98, 268-274.
12. Aggarwal, B.B.; Shishodia, S.; Sandur, S.K.; Pandey, M.K.; Sethi, G. Inflammation and cancer: How hot is the link? Biochem. Pharmacol. 2006, 72, 1605-1621. (Pubitemid 44666739)
13. Surh, Y.J.; Kundu, J.K. Cancer preventive phytochemicals as speed breakers in inflammatory signaling involved in aberrant COX-2 expression. Curr. Cancer Drug Targets 2007, 7, 447-458. (Pubitemid 47196204)
14. Kundu, J.K.; Surh, Y.J. Inflammation: Gearing the journey to cancer. Mutat. Res. 2008, 659, 15-30.
15. Cuendet, M.; Pezzuto, J.M. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol. Drug Interact. 2001, 17, 109-157.
16. Mann, J.R.; DuBois, R.N. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J. 2004, 10, 145-152. (Pubitemid 44313556)
17. King, K.L.; Cidlowski, J.A. Cell cycle regulation and apoptosis. Annu. Rev. Physiol. 1998, 60, 601-617. (Pubitemid 28157888)
18. Kerr, J.F.; Winterford, C.M.; Harmon, B.V. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994, 73, 2013-2026. (Pubitemid 24107952)
19. Kam, P.C.A.; Ferch, N.I. Apoptosis: Mechanisms and clinical implications. Anesthesia 2000, 55, 1081-1093.
20. Price-Whelan, A.; Dietrich, L.E.; Newman, D.K. Rethinking "secondary" metabolism: Physiological roles for phenazine antibiotics. Nat. Chem. Biol. 2006, 2, 71-78.
21. Li, D.; Wang, F.; Xiao, X.; Zeng, X.; Gu, Q.Q.; Zhu, W. A new cytotoxic phenazine derivative from a deep sea bacterium Bacillus sp. Arch. Pharm. Res. 2007, 30, 552-555.
22. Mitova, M.I.; Lang, G.; Wiese, J.; Imhoff, J.F. Subinhibitory concentrations of antibiotics induce phenazine production in a marine Streptomyces sp. J. Nat. Prod. 2008, 71, 824-827. (Pubitemid 351841430)
23. Conda-Sheridan, M.; Marler, L.; Park, E.-J.; Kondratyuk, T.P.; Jermihov, K.; Mesecar, A.D.; Pezzuto, J.M.; Asolkar, R.N.; Fenical, W.; Cushman, M. Potential chemopreventive agents based on the structure of the lead compound 2-bromo-1-hydroxyphenazine, isolated from Streptomyces species, strain CNS284. J. Med. Chem. 2010, 53, 8688-8699.
24. Laursen, J.; Nielsen, J. Phenazine natural products: Biosynthesis, synthetic analogues, and biological activity. Chem. Rev. 2004, 104, 1663-1685.
25. Kerr, J.R. Phenazine pigments: Antibiotics and virulence factors. Infect. Dis. Rev. 2000, 2, 184-194.
26. Shin-Ya, K.; Shimizu, S.; Kunigami, T.; Furihata, T.; Hayakawa, Y.; Seto, H. Novel neuronal cell protecting substances, aestivophoenins A and B, produced by Streptomyces purpeofuscus. J. Antibiot. 1995, 48, 1378-1381.
27. Marler, L.; Conda-Sheridan, M.; Cinelli, M.A.; Morrell, A.E.; Cushman, M.; Chen, L.; Huang, K.; van Breemen, R.B.; Pezzuto, J.M. Cancer chemopreventive potential of aromathecins and phenazines, novel natural product derivatives. Anticancer Res. 2010, 30, 4873-4882.
28. Imai, S.; Furihata, K.; Hayakawa, Y.; Noguchi, T.; Seto, H. Lavanducyanin, a new antitumor substance produced by Streptomyces sp. J. Antibiot. 1989, 42, 1196-1198. (Pubitemid 19193444)
29. Imai, S.; Noguchi, T.; Seto, H. Studies on cell growth stimulating substances of low molecular weight. Part 2. Exfoliazone and lavanducyanin, potent growth promoting substances of rat liver cell line, RLN-8, produced by Streptomyces exfoliatus and Streptomyces aeriouvifer. J. Antibiot. 1993, 46, 1232-1238. (Pubitemid 23266034)
30. Matsumoto, M.; Seto, H. Stimulation of mammalian cell proliferation by lavanducyanin. J. Antibiot. 1991, 44, 1471-1473.
31. Nakayama, O.; Arakawa, H.; Yagi, M.; Tanaka, M.; Kiyoto, S.; Okuhara, M.; Kohsaka, M. WS-9659 A and B, novel testosterone 5 alpha-reductase inhibitors isolated from a Streptomyces. III. Biological characteristics and pharmacological characteristics. J. Antibiot. 1989, 42, 1235-1240. (Pubitemid 19212666)
32. Asolkar, R.; Jensen, P.R.; Fenical, W. Marinophenazines, brominated antitumor-antibiotics from a marine bacterium related to the genus Streptomyces. J. Nat. Prod. submitted for publication.
33. Maiti, A.; Cuendet, M.; Kondratyuk, T.; Croy, V.L.; Pezzuto, J.M.; Cushman, M. Synthesis and cancer chemopreventive activity of zapotin, a natural product from Casimiroa edulis. J. Med. Chem. 2007, 50, 350-355. (Pubitemid 46147714)
34. Asolkar, R.N.; Freel, K.C.; Jensen, P.R.; Fenical, W.; Kondratyuk, T.P.; Park, E.J.; Pezzuto, J.M. Arenamides A-C, cytotoxic NF-κB inhibitors from the marine actinomycete Salinispora arenicola. J. Nat. Prod. 2009, 72, 396-402.
35. Choi, I.K.; Shin, H.J.; Lee, H.S.; Kwon, H.J. Streptochlorin, a marine natural product, inhibits NF-κB activation and suppresses angiogenesis in vitro. J Microb. Biotechnol. 2007, 17, 1338-1343.
36. Folmer, F.; Jaspars, M.; Dicato, M.; Diederich, M. Marine natural products as targeted modulators of the transcription factor NF-κB. Biochem. Pharmacol. 2008, 75, 603-617.
37. Ohsugi, T.; Horiel, R.; Kumasaka, T.; Ishida, A.; Ishida, T.; Yamaguchi, K.; Watanabe, T.; Umezawa, K.; Urano, T. In vivo antitumor activity of the NF-kB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 2005, 26, 1382-1388.
38. Chopra, P.; Bajpai, M.; Dastidar, S.G.; Ray, A. Development of a cell death-based method for the screening of nuclear factor-κB inhibitors. J. Immunol. Meth. 2008, 335, 126-131.
39. Frydrych, I.; Mlejnek, P. Serine protease inhibitors N-tosyl-L-lysinyl- chloromethylketone (TLCK) and N-tosyl-L-phenylalaninyl-chloromethylketone (TPCK) are potent inhibitors of activated caspase proteases. J. Cell. Biochem. 2008, 103, 1646-1656. (Pubitemid 351490729)
40. García, M.G.; Alaniz, L.; Lopes, E.C.; Blanco, G.; Hajos, S.E.; Alvarez, E. Inhibition of NF-κB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk. Res. 2005, 29, 1425-1434. (Pubitemid 41562245)
41. Chung, H.T.; Choi, B.M.; Kwon, Y.G.; Kim, Y.M. Interactive relations between nitric oxide (NO) and carbon monoxide (CO): Heme oxygenase-1/CO pathway is a key modulator in NO-mediated antiapoptosis and anti-inflammation. Meth. Enzymol. 2008, 441, 329-338.
42. Hofseth, L.J.; Hussain, S.P.; Wogan, G.N.; Harris, C.C. Nitric oxide in cancer and chemoprevention. Free Rad. Biol. Med. 2003, 34, 955-968. (Pubitemid 36398556)
43. Bhat, K.P.; Pezzuto, J.M. Cancer chemopreventive activity of resveratrol. Ann. NY Acad. Sci. 2002, 957, 210-229. (Pubitemid 34721666)
44. Santini, M.T.; Rainaldi, G.; Indovina, P.L. Apoptosis, cell adhesion and the extracellular matrix in the three-dimensional growth of multicellular tumor spheroids. Crit. Rev. Oncol. Hematol. 2000, 36, 75-87.
45. Weigert, A.; Jennewein, C.; Brune, B. The liaison between apoptotic cells and macrophages - the end programs the beginning. Biol. Chem. 2009, 390, 379-390.
46. Hoshino, J.; Park, E.J.; Kondratyuk, T.P.; Marler, L.; Pezzuto, J.M.; van Breemen, R.B.; Mo, S.; Li, Y.; Cushman, M. Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 2010, 53, 5033-5043.
47. Kim, Y.; Min, H.Y.; Park, H.J.; Lee, E.J.; Park, E.J.; Hwang, H.J.; Jin, C.; Lee, Y.S.; Lee, S.K. Suppressive effects of nitric oxide production and inducible nitric oxide synthase (iNOS) gene expression by Calystegia soldanella methanol extract on lipopolysaccharide-activated RAW 264.7 cells. Eur. J. Cancer Prev. 2004, 13, 419-424. (Pubitemid 39336607)
48. Park, E.-J.; Cheenpracha, S.; Chang, L.C.; Kondratyuk, T.P.; Pezzuto, J.M. Inhibition of lipopolysaccharide-induced cyclooxygenase-2 and inducible nitric oxide synthase expression by 4-[(2′-O-acetyl-α-L- rhamnosyloxy)benzyl]isothiocyanate from Moringa oleifera. Nutr. Cancer 2011, 63, 971-982.
49. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J.T.; Bodesch, H.; Kenney, S.; Boyd, M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Nat. Cancer Inst. 1990, 82, 1107-1112. (Pubitemid 20213250)
50. You, M.; Wickramaratne, D.B.; Silva, G.L.; Chai, H.; Chagwedera, T.E.; Farnsworth, N.R.; Cordell, G.A.; Kinghorn, A.D.; Pezzuto, J.M. Roemerine, an aporphine alkaloid from Annona senegalensis that reverses the multidrug-resistance phenotype with cultured cells. J. Nat. Prod. 1995, 58, 598-604.
51. Mi, Q.; Cui, B.; Silva, G.L.; Lantvit, D.; Lim, E.; Chai, H.; You, M.; Hollingshead, M.G.; Mayo, J.G.; Kinghorn, A.D.; et al. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype. Cancer Res. 2001, 61, 4030-4037.
52. Cuendet, M.; Mesecar, A.D.; DeWitt, D.L.; Pezzuto, J.M. An ELISA method to measure inhibition of the COX enzymes. Nat. Protoc. 2006, 1, 1915-1921. (Pubitemid 46773311)
53. Cao, H.; Yu, R.; Tao, Y.; Nikolic, D.; van Breemen, R.B. Measurement of cyclooxygenase inhibition using liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2011, 54, 230-235.
54. Yu, R.; Xiao, L.; Zhao, G.; Christman, J.W.; van Breemen, R.B. Competitive enzymatic interactions determine the relative amounts of prostaglandins E2 and D2. J. Pharmacol. Exp. Ther. 2011, 339, 716-725.
55. Prism 5 for Mac OSX, version 5.0c; GraphPad Software, Inc.: Mountain View, CA, USA, 2009.
56. Krishna, A.; Cabana, R. Flow cytometric analysis of electronic nuclear volume and DNA content in normal mouse tissues. Cell Cycle 2004, 3, 380-383. (Pubitemid 41359090)
57. Li, X.; Darzynkiewicz, Z. Labeling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Prolif. 1995, 28, 572-579.
58. Zhao, L.; Tao, J.-Y.; Zhang, S.-L.; Jin, F.; Pang, R.; Dong, J.-H. N-butanol extract from Melilotus Suaveolens Ledeb affects pro- and anti-inflammatory cytokines and mediators. Evid. Based Complement Alternat. Med. 2010, 7, 97-106.
59. Tsai, S.-H.; Lin-Shiau, S.-Y.; Lin, J.-K. Suppression of nitric oxide synthase and the down-regulation of the actvation of NFκB in macrophages by resveratrol. Br. J. Pharm. 1999, 126, 673-680. (Pubitemid 29087846)
60. Lee, S.K.; Mbwambo, Z.H.; Chung, H.S.; Luyengi, L.; Gamez, E.J.C.; Mehta, R.G.; Kinghorn, A.D.; Pezzuto, J.M. Evaluation of the antioxidant potential of natural products. Comb. Chem. High Throughput Screen. 1998, 1, 35-46. (Pubitemid 128541767)